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SUMMARY
Bisphenol A (BPA) is widely used in food contact materials, toys, and other products. Several studies have indicated that effects
observed at doses near human exposure levels may not be observed at higher doses. Many studies have shown effects on mammary
glands at low doses of BPA, however, because of small number of animals or few doses investigated these data have not been used by
EFSA as point of departure for the newly assessed tolerable daily intake (TDI). We performed a study with perinatal exposure to BPA
(0, 0.025, 0.25, 5, and 50 mg/kg bw/day) in rats (n = 22 mated/group). One of the aims was to perform a study robust enough to con-
tribute to the risk assessment of BPA and to elucidate possible biphasic dose–response relationships. We investigated mammary
gland effects in the offspring at 22, 100, and 400 days of age. Male offspring showed increased mammary outgrowth on pup day (PD)
22 at 0.025 mg/kg BPA, indicating an increased mammary development at this low dose only. Increased prevalence of intraductal
hyperplasia was observed in BPA females exposed to 0.25 mg/kg at PD 400, but not at PD 100, and not at higher or lower doses. The
present findings support data from the published literature showing that perinatal exposure to BPA can induce increased mammary
growth and proliferative lesions in rodents. Our results indicate that low-dose exposure to BPA can affect mammary gland develop-
ment in male and female rats, although higher doses show a different pattern of effects. The observed intraductal hyperplasia in
female rats could be associated with an increased risk for developing hyperplastic lesions, which are parallels to early signs of breast
neoplasia in women. Collectively, current knowledge on effects of BPA on mammary gland at low doses indicates that highly exposed
humans may not be sufficiently protected.
INTRODUCTION
The European Food Safety Authority (EFSA) concluded in an
opinion on bisphenol A (BPA) in January 2015 that the substance
is ‘likely’ to induce proliferative changes in mammary glands,
based on a weight-of-evidence approach (EFSA 2015). However,
EFSA evaluated that most of the studies on mammary gland
effects of BPA include too few doses or are in other ways not
robust and they could therefore not be used for deriving a tolera-
ble daily intake (TDI) for BPA.
Quite a few rodent studies have been performed on mammary
gland effects of pre- or perinatal exposure of BPA showing prolif-
erative lesions in the glands (Table 1). Although most of the
studies include few animals or only one or two BPA doses,
several studies showed effects at BPA levels around 0.025–
0.25 mg/kg bw/day. In general, effects were found in the lowest
doses investigated, but not at higher doses. Although non-mono-
tonic dose–response relationships are accepted in some scien-
tific fields today, it is still a controversial subject in other
scientific areas (Myers et al., 2009; Vandenberg et al., 2012,
2013a). The evidence on low-dose effects of BPA was further
challenged by the results of a large study by Delclos et al. (2014)
where significant mammary effects were only reported in the
highest doses investigated, and according to the authors, not at
lower doses around 0.025–0.25 mg/kg. As endpoints showing
low-dose effects in previous BPA studies (i.e. intraductal hyper-
plasia and epithelial proliferation) were not evaluated in adult
offspring in the Delclos study, it was considered necessary to
conduct this study on these (and other) endpoints in a large-
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scale study. This study aimed to strengthen the overall weight of
evidence regarding possible non-monotonic effects of perinatal
low-dose BPA exposure on rodent mammary glands.
Proliferative effects of BPA were seen in several studies: intra-
ductal hyperplasia, epithelial proliferation, and development of
more complex structures of the glands. The effects were mainly
found in adult female offspring, but in three studies proliferative
changes were also observed in prepubertal mammary glands
(Mu~noz-de-Toro et al., 2005; Delclos et al., 2014; Kass et al.,
2015) and in male mammary glands (Vandenberg et al., 2013b;
Kass et al., 2015). Thus, the presently available data point to pro-
liferative effects of BPA in both female and male mammary
glands of offspring exposed perinatally and the changes may be
observable at different time points.
Bisphenol A is known to act via estrogenic and anti-andro-
genic modes of action and has been shown to act via several
other toxicological modes of action (Bonefeld-Jørgensen et al.,
2007; Vandenberg et al., 2009; Zhang et al., 2011), but it is not
the scope of this manuscript to describe this in detail. The
mammary gland effects of BPA correspond to effects observed
by other estrogenic compounds, as for example, enhanced
mammary development prepubertally in female offspring has
been shown for several estrogenic compounds such as diethyl-
stilbestrol, 17b-estradiol, and genistein (Cotroneo et al., 2002;
Hovey et al., 2005; Thomsen et al., 2006). However, estrogenic
compounds can affect the glands in different ways other than
the ones described above. Enhanced lobular development has
been described previously for female rats exposed to estrogenic
compounds such as ethinyl estradiol and genistein (Murrill
et al., 1996; Takagi et al., 2004) and in our previous study on
perinatal exposure to phytoestrogens, a trend to an increased
prevalence of lobuloalveolar pattern of the adult female mam-
mary glands was observed (Boberg et al., 2013). Moreover,
enhanced mammary development and morphological changes
such as hypertrophy have been reported in males exposed to
estrogenic compounds (Mandrup et al., 2012; Boberg et al.,
2013). Thus, such changes may also be relevant to investigate
in mammary glands of offspring exposed to BPA.
The aim of this study was to supplement the existing data
available on mammary gland effects of BPA, to better establish
whether there are low-dose effects of BPA on mammary glands
and to better understand the dose–response relationships of BPA
on mammary glands. To do this, we applied perinatal exposure
of a sufficient number of rats to doses in the low-dose range
(lg/kg bw), where mammary changes have been reported by
others, as well as dose levels of BPA covering regulatory NOAELs
(mg/kg bw). The investigated endpoints included early mam-
mary gland development and different morphological changes
in mammary glands of young adult or aging male and female off-
spring exposed in the perinatal period. Proliferative changes of
pituitary glands were evaluated in the 1-year-old rats as previous
studies have shown that prolactinomas of the pituitary glands of
Table 1 Proliferative changes of mammary glands observed in rodent studies with prenatal or perinatal exposure to bisphenol A
Paper Doses in mg/kg Exposure
period
Exposure route Strain,
species
Effects
Markey et al. (2001) 0.025, 0.25 Prenatal Osmotic pump CD-1 mice Increased ductal & alveolar structures, 6 months (♀)
Markey et al. (2003) 0.000025,
0.00025
Prenatal Osmotic pump CD-1 mice Increased lobular structures at 6 months (♀)
Mu~noz-de-Toro
et al. (2005)
0.000025a,
0.00025b
Perinatal Osmotic pump CD-1 mice Increased number of lateral branchesa and number of
TEBs/mammary gland areab (p = 0.054
at 0.000025 mg/kg) PND 30 (♀)
Durando et al. (2007) 0.025 Prenatal Osmotic pump Wistar rats Intraductal hyperplasia PND 110 and 180 (♀)
Increased proliferative index PND 50
Murray et al. (2007) 0.0025,
0.025, 0.25, 1
Prenatal Osmotic pump Wistar-
furth rats
Intraductal hyperplasia PND 50 and 95 (♀)
Vandenberg et al. (2008) 0.00025,
0.0025, 0.025
Perinatal Osmotic pump CD-1 mice Increased number of alveolar buds, 3 months (♀)
Betancourt et al. (2010) 0.25 Prenatal Gavage SD rats Proliferation of epithelial cells PND 100 (♀)
Durando et al. (2011) 0.025, 0.25 Prenatal Osmotic pump Wistar rats Intraductal hyperplasia PND 110 but not PND 50 (♀)
Acevedo et al. (2013) 0.00025, 0.0025,
0.025, 0.25
Prenatal or
perinatal
Osmotic pump SD rats Adenocarcinomas observed PND 90, 140 and 200
(five animals in total in different BPA exposure groups)
but not statistically significant
Vandenberg
et al. (2013b)
0.00025c,
0.0025bc,
0.025a, 0.25
Perinatal Osmotic pump CD-1 mice Increased ductal area at 3–4 monthsb. Increased
branching points at 3–4 monthsc. Proliferation of
epithelial cells at 8 monthsa (two lowest doses
not investigated) (♂)
Delclos et al. (2014) 0.0025, 0.008,
0.025, 0.08,
0.26, 0.84, 2.7a,
100a, 300b
Perinatal and
postnatal
Gavage SD rats Increased ductal structures PND 21a and 90b (♀)
Branching and budding
DTU evaluation of
Delclos et al. (2014)c
0.0025, 0.008,
0.025, 0.08,
0.26, 0.84, 2.7,
100, 300
Perinatal and
postnatal
Gavage SD rats Evaluation of increased ductal structures PND 90
(with Fisher’s exact test for incidence of mild ductal
hyperplasia compared to na€ıve and vehicle controls) (♀)
Kass et al. (2015) A: 0.025, 0.25
B: 0.064
A: prenatal
B: perinatal
A: Osmotic
pump
B: Water
Wistar rats Increased outgrowth PND 5 (♂, A)
This study 0.025b,
0.25a, 5, 50
Perinatal Gavage Wistar rats aIntraductal hyperplasia PD 400 (♀), bincreased
outgrowth PD22 (♂)
Doses in bold are doses where statistically significant changes were observed for the effects listed in the column to the right. PND, postnatal day; TEBs, terminal end
buds; TDs, terminal ducts. a,bRefer to specific effects explained in the column to the right. cSee National Food Institute DTU (2015).
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elderly female rats may influence morphological changes in the
mammary glands (Trouillas et al., 1982).
Other endpoints were also evaluated in this study and results
on reproductive parameters and prepubertal data on offspring
are published in Christiansen et al. (2014) and data on adult
reproductive organs and behavioral effects are published in Hass
et al. (submitted to the current issue of Andrology).
MATERIALS ANDMETHODS
Chemicals
Bisphenol A (purity ≥99% pure, CAS no. 80-05-7, no. 239658)
was purchased from Sigma-Aldrich. Corn oil in glass bottles (no.
C8267) also purchased from Sigma-Aldrich was used as vehicle
and negative control. The dosing solutions were stirred continu-
ously, kept in glass bottles in the dark at room temperature and
verified by chemical analysis (reported in Christiansen et al.
2014).
Animals
A total of 110 time-mated female Wistar rats (HanTac : WH,
SPF from Taconic Europe, Ejby, Denmark) with a body weight of
200  20 g arrived on gestation day (GD) 3 and on GD 4. The
dams were distributed to five groups (n = 22 per group) with
similar weight distributions in all groups. The animals arrived in
three blocks with 1 week separating each block. The dose groups
were equally represented in the different blocks. Dams were
housed in pairs until GD 17. From this day and on dams were
housed alone. After weaning, offspring were housed in pairs.
Dams were housed in polysulfone cages (PSU 80-129HOOSU
Type III; Techniplast, Buguggiate, Italy, 15 9 27 9 43 cm) with
Aspen wood chip bedding (Tapvei, Gentofte, Denmark) and
Enviro Dri nesting material (Brogaarden, Lynge, Denmark) and
wooden shelters (Tapvei Arcade 17, Aspen wood; Brogaarden).
Animals had access to acidified tap water in BPA-free polysul-
fone water bottles (84-ACBT0702SU) and soy- and alfalfa free
diet (Altromin 1314, Altromin GmbH, Lage, Germany.) for breed-
ing animals. The PSU bottles and cages as well as the aspen
wood shelters (instead of plastic) were used to reduce the risk of
migration of BPA that potentially could confound the study
results. The animals were kept at 22  1 °C with a humidity of
55% 5, 10 air changes per hour and a light–dark cycle of 12–
12 h with lights on from 9 PM to 9 AM. Light and dark cycle was
reversed because of behavioral testing of the adult offspring,
which was done during their active period, that is, during the
dark cycle. Behavioral data are reported in Hass et al. (2016).
Dams were gavaged once daily with 0, 0.025, 0.25, 5, or 50 mg
BPA/kg bw/day from GD 7 to the day before expected birth (GD
21) and from the day after birth until pup day (PD) 22. PD 0 was
defined as the day of expected birth. The animal studies were
performed under conditions approved by the Danish Animal
Experiments Inspectorate (Council for Animal Experimentation,
authorization number: 2012-15-2934-00089) and by the in-house
Animal Welfare Committee of the National Food Institute at the
Technical University of Denmark.
Necropsies
Offspring were killed on PD 22, at 3–4 months of age (approxi-
mately PD 100) and at 13 months of age (approximately PD 400)
for mammary gland analysis. At necropsies at all ages, the
animals were anesthetized with O2/CO2 and decapitated. In each
age group, one offspring per sex per litter were selected for
necropsies. On PD 22, one abdominal (4th) mammary gland per
animal was dissected from the skin for whole mounting. Adult
males were killed on PD 90–115 and adult females on PD
104–129 (both males and females referred to as PD 100 in the fol-
lowing) and on PD 398–416 (referred to as PD 400 in the follow-
ing). No males were killed on PD 400. In adults, male and female
abdominal (4th) mammary glands with adjacent lymph nodes
were dissected and fixed in formalin for histology. On PD 400,
pituitary glands were additionally removed and gross lesions in
the pituitary glands were described. The pituitary glands were
weighted and fixed in formalin for histopathological evaluation.
Females were selected for necropsies when assessed to be in
estrous or proestrous, evidenced by vaginal smears in the morn-
ing showing macroscopically evident clots of epithelial cells as
described in OECD (2011b). As some females were killed hours
after selection in the morning, an additional vaginal smear was
performed at the time of killed for a more precise evaluation of
the stage of estrous cycle at sample selection. Assessment of the
estrous cycle at killed was assessed based on vaginal smears
only. Smears were stained with Papanicolaou stain as described
in Isling et al. (2014) and evaluated microscopically and classi-
fied in estrous or not in estrous. Estrous was defined as the pres-
ence of large amounts of cornified cells in the smear.
Mammary gland whole mounts
Whole mounts were fixed in formalin and stained with alum
carmine as described in Mandrup et al. (2015). Whole mounts
were scanned (4800 dpi) and analyzed also as described in
Mandrup et al. (2015), using IMAGE PRO PLUS 7.0 software (Media
Cybernetics, Bethesda, MD, USA). Mammary glands (n = 13–17
per dose group for females and n = 13–19 per group for males)
were evaluated for outgrowth (outer area defined as the small-
est polygon enclosing the gland, longitudinal growth (LG),
transverse growth (as defined by Mandrup et al., 2012), dis-
tance to the lymph node and distance to the fifth gland), the
number of terminal end buds (TEBs) in zone C (end buds with
a diameter ≥100 lm), and density (mean of scores given for
area, number of buds, number of branches, branch genera-
tions, and TEBs). Density scores were defined differently for
males and females and were therefore not comparable
between the sexes.
Histology of pituitary and mammary glands
Fixed tissue samples were routinely processed, embedded in
paraffin, sectioned (3 lm), stained with hematoxylin and eosin
(H&E), and examined blindly to treatment groups by light micro-
scopy. One section of pituitary glands from all female offspring
PD 400 was examined with emphasis on presence of nodular
hyperplasia and adenoma in pars distalis (MacKenzie & Boor-
man,1990). From females with gross lesions, an extra section
was examined if histological lesions were not observed in the
first section in the pituitary gland.
Histological examination of adult mammary glands (males
and females PD 100 and females PD 400) was performed on one
section of mammary gland. The glands were sectioned horizon-
tally as described in Hvid et al. (2011) and all ductular and alveo-
lar structures in the section were evaluated for each animal
(Hvid et al., 2011). The sections used for histological evaluation
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were representative of the mammary gland and deep enough to
include primary to tertiary ducts and a large number of both
ducts and lobular structures. Histological examination of adult
female mammary glands included the evaluation of lobular
development (lobule types ranging from single alveoli to well-
developed lobuli and lobular density), lobule morphology (shift
to male-like morphology with no lumens or small lumens and
multilayered epithelium), intraductal hyperplasia (four or more
layers of duct epithelium). To evaluate the extent of branching,
the density of ducts was evaluated in females PD 100. Four
females on PD 100 and 21 females on PD 400 were not found to
be in estrous at the time of killed. These were omitted from the
histological evaluation of lobular development because these
changes could be related to the estrous stage (Schedin et al.,
2000). Intraductal hyperplasia and changes in lobular morphol-
ogy toward a lobuloalveolar pattern (male-like) are not regarded
as normal cyclical changes in females, and all females were eval-
uated for such changes. Male mammary glands were evaluated
for tubuloalveolar pattern (female-like morphology with lumens
and single layered epithelium), secretory activity (dilated ducts
with secretory material in ductal or alveolar lumens and vacuo-
lated alveolar epithelium), and hypertrophy.
Statistics
Statistical analysis was performed in the statistical software SAS
Enterprise Guide 6.1 or GRAPHPAD PRISM 5. The statistical unit
(alpha level) was set at 0.05. Continuous data were evaluated for
homogeneity of variance before performing the statistical tests.
Data not fulfilling the criteria for homogeneity of variance (i.e.
distance to the lymph nodes and transverse growth in males)
were transformed accordingly. Continuous data (growth mea-
surements in whole mounts) were analyzed using an analysis of
variance (ANOVA) with body weight (bw) as a covariate and a Dun-
nett’s test to identify the effects of single treatments compared
to controls. To increase the power of the statistical analysis, data
for outer area were analyzed with an ANOVA with body weight as a
covariate and gender and litter as random factors. Testing for
non-monotonic dose–response relationships was performed by
at Tukey’s test for LSMeans.
Counting data and multi-leveled scoring data (i.e. density
scores and TEB data) were analyzed using a non-parametric test
(Kruskal–Wallis) with Dunn’s post hoc test correcting for multi-
ple comparisons. Histological scoring data were analyzed using
Fisher’s exact test (r 9 k for overall assessments and 2 9 k for
differences between two groups) or Chi-squared test unless
otherwise stated.
RESULTS
As reported in Christiansen et al. (2014), no general maternal
toxicity was observed at any of the administered doses. Further-
more, BPA exposure had no significant effect on maternal weight
gain, mean gestational length, post-implantation loss, litter size,
birth weights, sex ratio, perinatal loss, neonatal deaths, or off-
spring body weights in the postnatal period (Christiansen et al.,
2014).
Mammary gland whole mounts in prepubertal offspring
In prepuberty, BPA affected male, but not female, mammary
glands. An increased longitudinal growth and a decreased dis-
tance to the lymph node was observed in males in the lowest
dose group (0.025 mg/kg bw/day) (p = 0.05 and p = 0.02 in
Dunnett’s test, respectively) (Fig. 1), although this was not statis-
tically significant in the overall ANOVA (p = 0.10 and p = 0.07 for
longitudinal growth and distance to the lymph node, respec-
tively). These signs of increased outgrowth were supported by a
slight increase in the area of the gland in that dose group for
males and females (p = 0.07 in Dunnett’s test for pooled data
from males and females). No changes in density scores were
observed. Although the longitudinal growth and the distance to
the lymph node in males in the higher dose groups were some-
what similar to control levels, they were not statistically signifi-
cantly different from the 0.025 mg/kg exposure group when
analyzed with a Tukey’s test.
Mammary gland histology in adults
In females, histological examination of adult mammary
glands showed a statistically significant increase in intraductal
hyperplasia in females PD 400, but not PD 100. At PD 400,
intraductal hyperplasia was observed in all dose groups, but the
distribution and severity was increased in some BPA-dosed
groups compared to controls (Fig. 2). In controls, a mild degree
of intraductal hyperplasia affecting less than 30% of the mam-
mary tissue was seen in five of 20 animals. Extensive intraductal
hyperplasia (more than 30% of the mammary tissue) was
observed in five of 18 females in the group exposed to 0.25 mg/
kg BPA, but not in controls (p = 0.017, Fig. 2). The prevalence
of extensive intraductal hyperplasia seemed lower at 5 and
50 mg/kg BPA than at 0.25 mg/kg (affecting one of 18 females
at 5 mg/kg and two of 18 females at 50 mg/kg; Fig. 2). How-
ever, the difference between 0.25 and 5 mg/kg was not statisti-
cally significant (p = 0.18). Presence of adenomas or
hyperplasia in the pars distalis of pituitary glands were not cor-
related with intraductal hyperplasia or lobuloalveolar pattern,
as the prevalences of intraductal hyperplasias were comparable
in animals with and without pituitary hyperplasia (36 and 26%,
respectively). In 1-year-old females, fewer (yet not statistically
significant) exposed animals were irregularly cycling compared
to controls (Hass et al., 2016). It is therefore improbable that
the hyperplastic changes are related to changes in cycling. No
statistically significant changes were observed in lobular devel-
opment, lobular morphology in females PD 100 or 400 or in
branching in females PD 100.
In adult males, lobuloalveolar morphology is the typical mor-
phology of mammary glands (Cardy,1991; Wang et al., 2006). In
this study, some males showed lobuloalveolar morphology with
basally situated nuclei, resulting in a tubular-like orientation of
the epithelium, although a tubuloalveolar pattern with lumens
was not present. These changes were considered as an early shift
toward a female-like morphology. Areas of female-like morphol-
ogy (tubuloalveolar pattern or basal nuclei) of the male mam-
mary glands were seen in a few controls at PD 100. In the
highest dose group, this could be observed in the majority of
male mammary glands. A trend to increased frequency of males
with female-like morphology was observed in the two highest
dose groups (Fig. 3; p = 0.05 and 0.1 for the two highest doses in
a two-sided 2 9 2 Fisher’s exact test). Female-like structures can
appear in small amounts in controls as a normal background
variation in young males before full differentiation of the glands
to the male-like morphology (OECD, 2011a). On PD 100, male
mammary glands should be fully differentiated (Cardy, 1991),
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however, as the female-like changes in the current study were
observed in very few structures in each gland they may be
chance findings.
Histological evaluation of pituitary glands at PD 400
No statistically significant differences were observed between
exposed groups and controls in the incidence of pituitary gland
nodular hyperplasia and/or adenoma in pars distalis. A slightly
increased incidence of pituitary adenoma was found in the high-
dose BPA group (group 5), but this was not statistically signifi-
cant (Fig. 4).
DISCUSSION
Previous studies on mammary gland effects of perinatal BPA
exposure have shown proliferative changes in young and adult
female and male rodent offspring (Table 1). Just as in our study,
some of these changes are only seen at low, but not at high
doses, whereas other changes are seen mainly at the high-dose
levels. Data from the present and other mammary gland studies
on BPA all together suggest that perinatal exposure to BPA
induce effects that do not follow a classical monotonic dose–
response relationship. This cannot be readily explained, but a
pattern seems to appear when evaluating all available data
together. Table 1 lists the findings in this study together with
previous studies using more or less comparable study designs
for evaluation of BPA toxicity.
Female mammary gland effects
In this study, the main finding in female mammary glands was
an increased incidence of intraductal hyperplasia. In other stud-
ies, the proliferative changes reported in female rats span from
increased ductal area and number of ductal and alveolar struc-
tures to hyperplasia or proliferation of ductal epithelium
(Table 1). Interestingly, effects of BPA on intraductal hyperplasia
and proliferation have previously been seen in the lower dose
range up to 0.25 mg/kg in adults (Durando et al., 2007, 2011;
Murray et al., 2007; Betancourt et al., 2010) but not at higher
doses (Murray et al., 2007; Durando et al., 2011). Taken together
with the data from our study, it appears that the effects of BPA
on mammary gland hyperplasia and proliferation do not follow
a typical monotonic dose–response pattern. In contrast, effects
on growth and development are seen at 0.025 mg/kg and at
higher doses at prepuberty and in adults (Markey et al., 2001;
Delclos et al., 2014).
Strikingly, the hyperplastic changes were observed in adult
females although exposure did not continue into adulthood,
whereas effects in prepubertal female mammary glands were
weak or absent in this study. Accordingly, Markey et al. (2001)
and Durando et al. (2007) showed that changes in development
and epithelial proliferation of the female glands exposed to BPA
prenatally were only apparent after sexual maturation for expo-
sures corresponding to the low-dose range of our study (0.025
and 0.25 mg/kg) (Markey et al., 2001; Durando et al., 2007). In
Figure 1 Mammary gland outgrowth in offspring at PD 22 after perinatal exposure to 0, 0.025, 0.25, 5, or 50 mg/kg bw/day of bisphenol A (BPA). A statis-
tically significant increase in the longitudinal growth and decrease in the distance to the lymph node were seen in males exposed to BPA 0.025 mg/kg
(top). A related trend (p = 0.07) to an increased area was also observed in both males and females (bottom), although not statistically significant and with
large variations within groups. Individual values and means  SEM are shown. N = 13–16 for females and n = 13–19 for males.
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contrast, higher doses of BPA-induced effects on growth and
development in both prepubertal and adult female mammary
glands (Delclos et al., 2014). It is possible that different mecha-
nisms of action are prevailing at different dose levels. Estrogens
are known to have different effects at different doses at the cellu-
lar level (Amara & Dannies,1983; Soto & Sonnenschein,1987).
Overall, low doses of BPA appear to increase the risk for develop-
ing hyperplasia later in life, whereas higher doses appear to
increase early growth and development of the glands.
In accordance with our findings, previous studies have shown
intraductal hyperplasia in controls as well as in exposed animals,
but exposure to BPA increases the incidence (Durando et al.,
2007, 2011). In this study, the increased incidence of intraductal
hyperplasia was observed in BPA-exposed females from the dose
group exposed to 0.25 mg/kg bw/day, when the animals were
14 months of age, but not on PD 100. Such ductal changes have
also been reported in previous BPA studies at doses down to
0.025 and 0.0025 mg/kg and in younger females on PD 50, 110,
and PD 180 (Durando et al., 2007, 2011; Murray et al., 2007). In
those studies, a quantitative technique was used for histological
evaluation, and it is possible that using a quantitative technique
instead of a scoring technique could have improved our ability
to detect small changes at the lower dose (0.025 mg/kg) or at an
earlier age. When evaluating histological data, it is highly rele-
vant to consider that even perinatally induced lesions may
become more severe at increasing ages. For example, studies in
female rats exposed to a carcinogen on PND21 revealed an
increased incidence of intraductal hyperplasia with increasing
age (Thompson et al., 1998, 2000). Thus, at increasing ages it
may become easier to detect treatment-related effects with
crude methods such as scoring evaluation of only one section
per tissue per animal, as long as control levels are relatively low.
Despite a risk of more background ‘noise’ at increasing age, it
seems warranted to continue investigating mammary glands in
older females, and at the same time to continue development of
more sensitive methods for mammary gland evaluation in
younger animals. Further development of quantitative methods
may increase the sensitivity of mammary gland examination
using the whole-mount method or histological examination.
BPA-induced intraductal hyperplasia (Durando et al., 2007,
2011; Murray et al., 2007) and increased mammary development
(Mu~noz-de-Toro et al., 2005; Moral et al., 2008; Ayyanan et al.,
2011) may not be rodent specific. A study in Rhesus monkeys also
showed increased mammary development in female offspring few
days after birth following prenatal exposure to BPA (Tharp et al.,
2012). In general, the intraductal hyperplasia observed in these
studies is comparable to hyperplasia observed in human breasts
(Singh et al., 2000) and are likely to be preneoplastic lesions
(Thompson et al., 1998). Several studies have shown increased
susceptibility to mammary carcinogens after perinatal exposure to
(A)
(B) (C)
Figure 2 Female mammary gland histology at PD 400 after perinatal exposure to 0, 0.025, 0.25, 5, or 50 mg/kg bw/day of bisphenol A (BPA). (A) Distribu-
tion of scores for intraductal hyperplasia. Extensive intraductal hyperplasia (more than 30% of the gland) was observed in a significantly higher prevalence
of females in the group exposed to 0.25 mg/kg BPA compared to controls (Fisher’s exact test p = 0.017). *p < 0.05 for high intraductal hyperplasia (more
than 30% of tissue), Fisher’s exact 2 9 2 test. (B) Typical duct from control female with a single layer of duct epithelium. (C) Example of duct with intraduc-
tal hyperplasia in a female exposed perinatally to 0.25 mg/kg BPA. Bars in the lower right corner of pictures B and C represent 25 lm. N = 18–21.
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BPA as reviewed by Soto et al. (Soto et al., 2013). For example,
exposure to a subcarcinogenic level of N-nitroso-N-methylurea
(NMU) induced malignant tumors in females prenatally exposed
to BPA (Durando et al., 2007). Acevedo and co-workers found ade-
nocarcinomas in females exposed to BPA, but not in controls,
although the animals were not exposed to a carcinogen later in life
(A)
(B) (C)
Figure 3 Male mammary gland histology at PD 100 after perinatal exposure to 0, 0.025, 0.25, 5, or 50 mg/kg bw/day of bisphenol A (BPA). (A) Histologi-
cal evaluation showed exposed males with female-like morphology of the mammary glands (tubuloalveolar morphology or epithelium with basally situated
nuclei) in all groups. A trend to increased number of males with female-like pattern was observed in the two highest dose groups (p = 0.05 for 5 mg/kg and
p = 0.1 for 50 mg/kg BPA in a 2 9 2 Fisher exact test). N = 17–22. (B) Control male mammary gland with lobuloalveolar pattern. (C) Male from the high-
est exposure group (50 mg/kg bw/day) with tubuloalveolar morphology of the mammary gland. Bars in B and C represent 100 lm.
Figure 4 Pituitary gland histology in female offspring at PD 400 after perinatal exposure to 0, 0.025, 0.25, 5, or 50 mg/kg bw/day of bisphenol A (BPA).
Percentages of female offspring with focal nodular hyperplasia (black), adenoma (dark gray), or with presence of few atypical cells without compression of
surrounding tissue (light gray) in the pars distalis of the pituitary gland are shown. N = 20, 21, 18, 19, 18, respectively. No statistical significant differences
were observed between exposed groups and controls.
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(Acevedo et al., 2013). Accordingly, our observation of increased
intraductal hyperplasia at PD 400 may thus indicate a higher risk
for developing hyperplasia and mammary tumors in adulthood.
In general, the present findings indicate that BPA may con-
tribute to precocious breast development and increase the risk
for breast cancer in perinatally exposed individuals.
Male mammary gland effects
Interestingly, male mammary gland development also appears
to be affected by BPA in a similar way as female mammary
glands. Proliferative changes are found in males at different ages,
as an increased outgrowth prepubertally was seen in this study
and reported by Kass et al. (2015), and as an increased ductal
area, increased number of branching points, and increased pro-
liferation of epithelial cells was reported in adults (Vandenberg
et al., 2013b). Proliferative changes (hyperplasia) were not inves-
tigated in adult males in this study as evaluation of hyperplasia
is hampered by the lobuloalveolar morphology of well-differen-
tiated male mammary glands. Together, data suggest that male
mammary gland development is increased by perinatal BPA
exposure. In this study, mammary proliferative changes were
observed already before sexual maturation of males, and already
at the lowest dose of BPA (0.025 mg/kg). Based on the findings
in male mammary glands, no NOAEL could be established for
mammary gland effects in this study. This supports other studies
showing absence of NOAEL for mammary changes in males
down to the lowest dose tested, that is, 0.00025 mg/kg (corre-
sponding to 0.25 lg/kg) (Vandenberg et al., 2013b). Overall,
there is a strong weight of evidence for mammary effects of peri-
natal BPA exposure in the lg/kg dose range.
Altogether, our data support previous studies showing that
male mammary glands are susceptible to BPA exposure, and that
male gland development can be more sensitive to endocrine dis-
ruption than female mammary glands (You et al., 2002; Man-
drup et al., 2012). Male mammary glands are rarely examined
when investigating chemicals suspected to be endocrine disrupt-
ing although effects may be detected earlier or at lower doses in
males than in females. The implications of the findings observed
in male rats are not known, but these changes may suggest that
boys and men exposed to endocrine disrupters can develop
more breast tissue and thus increase the susceptibility for
gynecomastia.
Non-monotonic dose–response effects on mammary glands
The most marked effects observed in male and female mam-
mary glands were seen at the lower doses tested and results at
the higher doses approached control levels suggesting a non-
monotonous dose–response curve for mammary gland effects.
Indications of non-monotonic dose–response curves for BPA
have been described by others for proliferative mammary gland
changes at different ages, showing statistically significant effects
at doses of 0.0025 mg/kg in 95-days old females (Murray et al.,
2007), 0.025 mg/kg in 110 days old females (Durando et al.,
2011), and 0.025 mg/kg in 7–9 months old males (Vandenberg
et al., 2013b) but not at higher doses. Additionally, such non-
monotonic dose–response curves have also been reported for
changes in gland development. Studies have shown significant
effects on the number of branch points at 0.00025 and
0.0025 mg/kg BPA but not at higher doses in 3–4 months old
male offspring (Vandenberg et al., 2013b) and changes in ductal
elongation with significant differences between 0.025 and
0.25 mg/kg BPA in 1-month old offspring (Markey et al., 2001).
Interestingly, Delclos et al. (2014) only found significant
effects (increased number of ductal structures) in mammary
glands in the highest doses investigated, although they included
doses of 0.025 and 0.26 mg/kg BPA and investigated a large
number of animals. It should be noted, however, that endpoints
showing low-dose effects in previous BPA studies and in this
study (i.e. intraductal hyperplasia and epithelial proliferation)
was not evaluated in adult offspring in the Delclos study
(Table 1). Moreover, pups were dosed by gavage postnatally
from PND1 and the exposure period in that study persisted until
killed in adulthood and these differences in study design may
have implications on the mammary gland development. Reason-
ably enough, Delclos et al. (2014) performed the statistical anal-
ysis in two subgroups to minimize false negative results, as they
included many exposure groups (two control groups, nine BPA
exposure groups and two ethinyl estradiol exposure groups) in
their study. Yet, the distribution of the exposure groups in the
statistical subgroups favored the high-dose groups (100 and
300 mg/kg), as all other seven BPA exposure groups were ana-
lyzed statistically together, leading to a higher risk for false nega-
tive results in all the low-dose groups compared to the two
highest dose groups. If the exposure groups had been distributed
equally in two subgroups (e.g. the five lowest doses in one group
for statistical analysis and the four highest doses in another
group), the results may have shown significant effects in other
exposure groups. We have tentatively analyzed the data on duct
hyperplasia presented in Delclos et al. (2014) in an alternative
way (using Fisher’s exact test) and found significantly increased
frequencies of duct hyperplasia in 3-months old females down
to 0.08 mg/kg bw/day (National Food Institute DTU, 2015)
(Table 1).
Non-monotonic dose–response curves have been observed for
other endpoints in this BPA study. Data on spatial learning and
sperm count showed significant effects at the lowest dose but
not at higher doses (Hass et al., 2016). Data from the present
and other mammary gland studies on BPA all show that effects
are seen in the lower dose range up to 0.25 mg/kg and again at
much higher doses (Table 1). Altogether, the available data sug-
gest that proliferative effects of perinatal exposure to BPA on
mammary glands do not follow a classical monotonic dose–re-
sponse relationship.
Overall, strong evidence points to mammary effects of perina-
tal BPA exposure at dose levels in the lg/kg area, around
0.25 mg/kg/day or lower suggesting that the new temporary TDI
for BPA set by EFSA of 4 lg/kg bw/day is not sufficiently protec-
tive with regard to endocrine disrupting effects in humans.
Pituitary gland histology at PD 400
Pituitary adenomas were observed in all groups as expected
because spontaneous pituitary adenomas are a common finding
in aged rats (Trouillas et al., 1982; Barsoum et al., 1985; Carlus
et al., 2013). Increased incidence of pituitary adenoma has previ-
ously been shown in aged Wistar rats perinatally exposed to mix-
tures of endocrine disrupting chemicals, especially for a mixture
of predominantly anti-androgenic chemicals (Isling et al., 2014).
However, in this study no statistically significant differences in
the incidence of pituitary focal nodular hyperplasia and/or ade-
noma were observed between BPA-exposed groups and controls
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and no associations between pituitary hyperplasia and/or ade-
nomas and mammary intraductal hyperplasia were seen.
Although not immunohistochemically confirmed, a high num-
ber of the pituitary adenomas seen in the available studies are
likely to be prolactinomas, which commonly occur in aging rats
(Trouillas et al., 1982; Barsoum et al., 1985). Prolactinomas can
be induced in rats by prolonged administration of estrogen, as
estrogen is known to stimulate prolactin release from lac-
totrophs and inhibit the activity of hypothalamic neuroen-
docrine dopaminergic neurons (Welsch et al., 1971; Sarkar et al.,
1982; DeMaria et al., 2000; Lloyd, 2015). Consequently, endo-
crine-disrupting chemicals with estrogenic activity could be
speculated to influence the development of pituitary adenoma
and the specific types of adenomas, but no relation to BPA expo-
sure was seen in this study. Further studies on prolactin serum
levels and immunohistochemistry of pituitary glands could
enlighten the nature of the hyperplasias and adenomas observed
in controls and exposed animals.
CONCLUSION
Our study confirmed the findings reported by others, showing
intraductal hyperplasia in the lg/kg bw dose area but not at
higher doses of BPA. Moreover, male mammary development
was increased in the lowest dose investigated, that is, 25 lg/kg
bw per day but not at higher doses and no NOAEL was deter-
mined for mammary gland effects. This effect observed in rats at
25 lg/kg bw per day indicate that the new temporary TDI of
4 lg/kg bw per day proposed by EFSA is not sufficiently protec-
tive with regard to effects on mammary gland development.
In this study, effects of BPA on mammary gland development
was found at 0.025 or 0.25 mg/kg BPA depending on the end-
point, method, and age of investigation. The effects observed in
this low-dose range are considered likely to be treatment-related
effects although no significant effects are observed at higher
doses and a classical monotonic dose–response curve is not
observed. The available data on BPA effects on mammary glands
support that non-monotonic dose–response relationships for
these effects occurs. As these effects are expected to be related to
the endocrine-disrupting mode of action of BPA, the results indi-
cate that also other endocrine disruptors may show non-mono-
tonic dose–response relationships for mammary gland effects
with effects occurring only at the lower doses. In future studies
on endocrine disrupters, it is therefore recommended to con-
sider inclusion of low doses. Also, in risk assessment of endo-
crine disrupters there is a need for more awareness that non-
monotonic dose–response relationships can occur.
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MEETING COMMENTS
Martine Applanat (Paris, France)
There is controversy concerning the lower doses of bisphenol
A (BPA) and their effects on the mammary gland. I was surprised
that you saw hyperplasia of the intraduct epithelium at 400 post-
natal days but not before following a dose of 250 lg/kg/day.
Some technical details must be considered in order to interpret
the results. Were the housekeeping cages controlled and BPA
free? Was the diet phytoestrogen-free? Did you measure blood
BPA concentration and what was the lowest detectable level? At
what stage of the estrous cycle were the rats sacrificed? Measure-
ment of these parameters is fundamental for the evaluation of
the statistical effect of the results.
Karen Riiber Mandrup (Søborg, Denmark)
We did not identify intraductal hyperplasia before the age of
14 months, although this has been described in other studies. In
other studies, hyperplasia at an earlier age was detected using
more quantitative methods including taking several serial histo-
logical sections of each gland and counting the cells. We only
scored one section per gland and were less likely to detect minor
changes at an earlier age. Our cages and drinking bottles were
BPA free. The diet was selected to be soy and alphaalpha free.
Our conditions were controlled to minimize contamination from
the environment.
Pete Myers (Charlottesville, USA)
It is good to see that you have replicated Ana Soto’s work espe-
cially as you work for a Government agency. You cited the study
of Delclos et al. (2014) which differed from other studies in that
low-dose levels were not significantly different from their con-
trols. That paper should not be considered because the controls
were contaminated with BPA and the results are not reliable.
Karen Riiber Mandrup
We can discount their apparent lack of low-dose effect. How-
ever, their higher doses were greater than the control levels and
the effects seen in those animals are valid.
David Kristiansen (Copenhagen, Denmark)
Have you studied the mechanism of the intraduct hyperplasia
to see if there is signal transduction, and have you examined the
adipocytes after exposure to BPA? It is known that growth of
alveolar cells comes from fat cells by a process of transdifferenti-
ation because of signaling from the gonad.
Karen Riiber Mandrup
We have not investigated the mechanisms behind the changes
observed.
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